Biosceptre has established a strong pipeline for oncology immunotherapy against nfP2X7 spanning a range of therapeutic modalities.

Our data has shown that drugs directed to nfP2X7 have the potential to treat many common as well as rare cancers whilst avoiding the toxicity seen with many marketed cancer drugs. We have exploited this unique profile by developing a pipeline of discovery and clinical programmes against cancer.

Biosceptre Pipeline of Therapeutics targeting nfP2X7.

The most advanced of Biosceptre’s development programmes is BIL010t, consisting of polyclonal antibodies in a topical formulation to treat basal cell carcinoma (BCC), locally advanced BCC, and other skin cancers. This programme has already delivered excellent safety and tolerability data alongside a strong indication of efficacy in man This data was published recently.

Biosceptre’s second clinical programme is, BIL06v, a therapeutic anti-cancer vaccine which is ready to enter a Phase I clinical trial.

Biosceptre’s third clinical programme is BIL03s, a human domain antibody for systemic administration to treat a variety of tumours which is ready to enter a Phase I clinical trial.

Biosceptre’s proprietary target nfP2X7 has important potential advantages over current chemotherapy, radiation and other oncology immunotherapies including:

  • Low toxicity: Formal toxicity trials and a successful phase I trial confirm a good safety profile for therapeutics targeting nfP2X7
  • Selectivity: nfP2X7 is expressed on cancer cells and absent from the surface of normal cells
  • Breadth of application across a broad range of cancers: nfP2X7 is broadly expressed on multiple cancers including but not limited to breast, prostate, lung, melanoma and bladder.

Biosceptre is also developing additional modalities to target nfP2X7.

In addition, detection of nfP2X7 has potential as a powerful diagnostic approach (Published paper). Biosceptre is also investigating development of companion diagnostics based on targeting nfP2X7.